Credit Suisse’s Insys Therapeutics, Inc. INSY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
Sell
-18,869
Closed -$86K 4322
2019
Q1
$86K Buy
18,869
+3,626
+24% +$17.2K ﹤0.01% 3864
2018
Q4
$53K Buy
15,243
+2,625
+21% +$18.2K ﹤0.01% 3796
2018
Q3
$127K Sell
12,618
-7,150
-36% -$57K ﹤0.01% 3706
2018
Q2
$143K Sell
19,768
-692
-3% -$4.83K ﹤0.01% 3803
2018
Q1
$124K Sell
20,460
-61,468
-75% -$508K ﹤0.01% 3773
2017
Q4
$790K Buy
81,928
+48,717
+147% +$319K ﹤0.01% 3161
2017
Q3
$295K Buy
33,211
+12,087
+57% +$125K ﹤0.01% 3754
2017
Q2
$267K Sell
21,124
-9,879
-32% -$117K ﹤0.01% 3525
2017
Q1
$326K Buy
31,003
+2,362
+8% +$25.2K ﹤0.01% 3492
2016
Q4
$264K Sell
28,641
-12,983
-31% -$147K ﹤0.01% 3713
2016
Q3
$491K Sell
41,624
-15,184
-27% -$231K ﹤0.01% 3434
2016
Q2
$735K Sell
56,808
-25,339
-31% -$369K ﹤0.01% 3176
2016
Q1
$1.31M Buy
82,147
+33,331
+68% +$633K ﹤0.01% 2524
2015
Q4
$1.4M Buy
48,816
+4,696
+11% +$130K ﹤0.01% 2550
2015
Q3
$1.26M Sell
44,120
-80,119
-64% -$2.95M ﹤0.01% 2621
2015
Q2
$4.46M Buy
124,239
+59,371
+92% +$1.85M ﹤0.01% 1848
2015
Q1
$1.89M Sell
64,868
-40,952
-39% -$1.08M ﹤0.01% 2439
2014
Q4
$2.23M Sell
105,820
-46,524
-31% -$920K ﹤0.01% 2454
2014
Q3
$2.95M Buy
152,344
+120,822
+383% +$1.9M ﹤0.01% 2182
2014
Q2
$493K Sell
31,522
-28,714
-48% -$464K ﹤0.01% 3833
2014
Q1
$1.25M Buy
60,236
+2,396
+4% +$47.5K ﹤0.01% 2921
2013
Q4
$747K Buy
57,840
+9,165
+19% +$127K ﹤0.01% 3500
2013
Q3
$568K Buy
+48,675
New +$400K ﹤0.01% 3420

Other funds holding INSY

Credit Suisse's INSY Position: Q2 2019 in Review

Credit Suisse sold out of Insys Therapeutics, Inc. (INSY) in Q2 2019, closing a stake of 18,869 shares — an estimated $86K sold.

Credit Suisse first reported a position in INSY in Q3 2013 and held it in 23 quarters. The position peaked at $4.46M in Q2 2015. 16 funds tracked by Wall St. Rank hold INSY as of Q2 2019.

  • Credit Suisse reported no remaining Insys Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • Credit Suisse sold 18,869 Insys Therapeutics, Inc. shares in Q2 2019, an estimated $86K.
  • Credit Suisse first reported a position in Insys Therapeutics, Inc. in Q3 2013 and held it in 23 quarters.
  • Credit Suisse's Insys Therapeutics, Inc. position peaked at $4.46M in Q2 2015.
  • 16 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2019.

Based on Credit Suisse's 13F filing for Q2 2019, filed 14 Aug 2019.